Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 5
1999 1
2000 1
2001 1
2002 3
2003 4
2006 3
2007 2
2008 3
2009 4
2010 4
2011 6
2012 5
2013 6
2014 8
2015 6
2016 6
2017 7
2018 4
2019 4
2020 1
2021 4
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis.
Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Jaafar MH, et al. Dig Dis Sci. 2018 May;63(5):1250-1260. doi: 10.1007/s10620-017-4871-9. Epub 2017 Dec 1. Dig Dis Sci. 2018. PMID: 29192375 Review.
OBJECTIVE: The role of gastritis in dyspepsia remains controversial. We aimed to examine the efficacy of rebamipide, a gastric mucosal protective agent, in both organic and functional dyspepsia. ...Overall, dyspepsia symptom improvement was significantly better with reb …
OBJECTIVE: The role of gastritis in dyspepsia remains controversial. We aimed to examine the efficacy of rebamipide, a gastric mucosa …
Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis.
Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y. Zhang S, et al. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0. Epub 2013 Feb 28. Dig Dis Sci. 2013. PMID: 23456504 Review.
Randomized controlled trials (RCTs) recruiting subjects with co-prescriptions of NSAIDs and rebamipide were eligible. Efficacy and safety of rebamipide were reevaluated, and dichotomous data were pooled to obtain relative risk (RR) with a 95 % confidence interval. . …
Randomized controlled trials (RCTs) recruiting subjects with co-prescriptions of NSAIDs and rebamipide were eligible. Efficacy and sa …
Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial.
Eom Y, Chung SH, Chung TY, Kim JY, Choi CY, Yoon KC, Ko BY, Kim HK, Kim MK, Lee HK, Song JS, Hyon JY, Seo KY, Lee JS, Kim HM. Eom Y, et al. BMC Ophthalmol. 2023 Aug 3;23(1):343. doi: 10.1186/s12886-023-03004-1. BMC Ophthalmol. 2023. PMID: 37537533 Free PMC article. Clinical Trial.
BACKGROUND: To evaluate the efficacy of 1% and 2% rebamipide clear solution in the treatment of dry eye disease (DED). METHODS: Two hundred twenty patients with DED were randomly assigned to one of three groups: the 1% rebamipide, 2% rebamipide, or placebo (e …
BACKGROUND: To evaluate the efficacy of 1% and 2% rebamipide clear solution in the treatment of dry eye disease (DED). METHODS: Two h …
Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study.
Lee JS, Jeon SW, Lee HS, Kwon YH, Nam SY, Bae HI, Seo AN. Lee JS, et al. Dig Dis Sci. 2022 Jun;67(6):2395-2402. doi: 10.1007/s10620-021-07038-7. Epub 2021 May 30. Dig Dis Sci. 2022. PMID: 34052947 Clinical Trial.
Fifty-three (rebamipide, n = 34 vs. placebo, n = 19) patients, who underwent endoscopic resection for gastric dysplasia or early GC, were analyzed. ...CONCLUSIONS: This study demonstrated that the administration of rebamipide improves AG and IM in the antrum, especi …
Fifty-three (rebamipide, n = 34 vs. placebo, n = 19) patients, who underwent endoscopic resection for gastric dysplasia or early GC, …
The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study.
Oh DJ, Yoon H, Kim HS, Choi YJ, Shin CM, Park YS, Kim N, Lee DH, Ha YJ, Kang EH, Lee YJ, Kim N, Kim KJ, Liu F. Oh DJ, et al. Korean J Intern Med. 2022 Nov;37(6):1153-1166. doi: 10.3904/kjim.2021.216. Epub 2022 Nov 1. Korean J Intern Med. 2022. PMID: 36375487 Free PMC article. Clinical Trial.
This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump inhibitor administration in patients requiring long-term NSAID use. ...Furthermore, fewer side-effects emerged with rebamipide....
This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump …
Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis.
Liu J, Xiong Z, Geng X, Cui M. Liu J, et al. Biomed Res Int. 2020 Sep 28;2020:7196782. doi: 10.1155/2020/7196782. eCollection 2020. Biomed Res Int. 2020. PMID: 33062694 Free PMC article.
OBJECTIVE: To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone for the treatment of endoscopic submucosal dissection (ESD-) induced ulcers. ...In addition, rebamipide plus PPI therapy was discovered to be significantly more effe …
OBJECTIVE: To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone for the treatment of endoscopic …
Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N; Rebamipide Ophthalmic Suspension Phase II Study Group. Kinoshita S, et al. Ophthalmology. 2012 Dec;119(12):2471-8. doi: 10.1016/j.ophtha.2012.06.052. Epub 2012 Sep 23. Ophthalmology. 2012. PMID: 23009892 Clinical Trial.
METHODS: After a 2-week screening period, patients were randomized to receive placebo or 1% rebamipide or 2% rebamipide administered as 1 drop in each eye 4 times daily for 4 weeks. ...Although 1% and 2% rebamipide were both efficacious, 2% rebamipide …
METHODS: After a 2-week screening period, patients were randomized to receive placebo or 1% rebamipide or 2% rebamipide admini …
Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis.
Baptist J, Shakya S, Ongole R. Baptist J, et al. J Contemp Dent Pract. 2016 Dec 1;17(12):1009-1012. J Contemp Dent Pract. 2016. PMID: 27965488 Clinical Trial.
MATERIALS AND METHODS: Twenty OSF patients were divided into two groups [rebamipide (100 mg TID for 21 days) and betamethasone (4 mg/mL biweekly for 4 weeks)] of 10 each by random sampling. ...CLINICAL SIGNIFICANCE: Considering stomatopyrosis and trismus as a major cause f …
MATERIALS AND METHODS: Twenty OSF patients were divided into two groups [rebamipide (100 mg TID for 21 days) and betamethasone (4 mg/ …
Efficacy and safety of proton pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis.
Wang J, Guo X, Ye C, Yu S, Zhang J, Song J, Cao Z, Wang J, Liu M, Dong W. Wang J, et al. Intern Med. 2014;53(12):1243-8. doi: 10.2169/internalmedicine.53.2160. Epub 2014 Jun 15. Intern Med. 2014. PMID: 24930641 Free article. Review.
OBJECTIVE: To compare the efficacy of proton pump inhibitors (PPIs) with rebamipide versus PPIs alone for the treatment of ulcers after endoscopic submucosal dissection (ESD). ...CONCLUSION: The results of this meta-analysis suggest that treatment with PPIs plus rebamip …
OBJECTIVE: To compare the efficacy of proton pump inhibitors (PPIs) with rebamipide versus PPIs alone for the treatment of ulcers aft …
Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.
Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G. Gagliano-Jucá T, et al. BMC Gastroenterol. 2016 Jun 4;16(1):58. doi: 10.1186/s12876-016-0472-x. BMC Gastroenterol. 2016. PMID: 27259970 Free PMC article. Clinical Trial.
BACKGROUND: Rebamipide is a gastroprotective agent with promising results against gastric damage induced by non-steroidal anti-inflammatory drugs. The present study evaluated if rebamipide protects against naproxen-induced gastric damage in healthy volunteers. ...
BACKGROUND: Rebamipide is a gastroprotective agent with promising results against gastric damage induced by non-steroidal anti-inflam …
83 results

Searches related to "rebamipide"